HOME >> BIOLOGY >> NEWS
New analysis gives cancer patients personalized prognosis

DURHAM, N.C. -- Researchers at Duke University have developed a new analytical approach that combines genetic and clinical data to give cancer patients an individualized prognosis of their cancer recurrence. The information could prove critical in deciding how aggressively to treat the disease following surgery.

The researchers reported their findings using breast cancer as a test case in the April 26, 2004, online early edition of the Proceedings of the National Academy of Sciences.

"Currently, it is primarily traditional clinical information alone that aids in understanding a patient's risk profile," said Mike West, Ph.D., Arts & Sciences professor of statistics and decision sciences at Duke and lead author on the study. "However, the resulting predictions typically lump patients into broad categories. Access to detailed genomic information now provides the opportunity to move far beyond this -- toward customized risk predictions and prognoses more widely, for the individual patient."

Nevertheless, most previous studies that have focused on developing genomic-based predictors of cancer recurrence risk have only broadly defined patients as high versus low risk, leaving considerable room for error about an individual's true chance of recurrence, the researchers said. The power of the Duke team's approach to improve such predictions lies in the combined use of multiple sources of clinical and genomic data, they said.

In their case study of breast cancer, the Duke team developed methods that utilize diverse information including traditional clinical variables, such as lymph node and estrogen receptor status, and multiple, complex patterns of gene activity, or "genetic fingerprints," of a patient's tumor. They integrated these data to formulate unique predictions about individual patients' recurrence risk. While the Duke study focused on patients with breast cancer, the approach is applicable more broadly to any form of cancer and can in
'"/>

Contact: Kendall Morgan
kendall.morgan@duke.edu
919-684-4148
Duke University Medical Center
26-Apr-2004


Page: 1 2 3 4

Related biology news :

1. Human chromosome 5 final sequence analysis released to public
2. Genetic analysis rewrites salamanders evolutionary history
3. Proven method of bone analysis may clarify human origins
4. Carnegie Mellon U. conducts first comprehensive proteomic analysis of developing animal
5. Online calculator improves analysis of chemical data
6. Scientists discover way to streamline analysis of maize genome
7. Automated analysis of bee behavior may yield better robots
8. High-tech analysis of vineyard soil
9. SARS virus can change quickly and unpredictably, analysis indicates
10. Human rights in Peru: AAAS analysis doubles previous estimates of killings
11. Global analysis finds a large portion of the earth is still wilderness

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2020)... ... August 06, 2020 , ... Alucio™, a fast-growing provider ... Eric Chen and Jessica Wong have joined the company’s leadership team as Vice ... Eric Chen heads development efforts for Alucio’s flagship product, Beacon, an innovative cloud-based ...
(Date:8/5/2020)... Fla. (PRWEB) , ... August 05, 2020 , ... Regenative ... cover two new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts ... defect using a syringe. The company’s solutions are the first Wharton’s jelly allograft product ...
(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, Inc. today announced a ... Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of ... a highly efficient mammalian cell culture-based bioprocess suitable to meet surge requirement needs ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... Editas Medicine, Inc. (Nasdaq: ... advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ... strategic partnership whereby Catalent will provide support for the development, manufacturing, and clinical ...
(Date:7/22/2020)... TORONTO (PRWEB) , ... July 22, 2020 , ... Join ... and John Lorenc, Sr. Manager Regulatory Solutions, in a one hour live webinar ... is the regulating body in China for drugs and medical devices. Specifically, for medical ...
(Date:7/18/2020)... ... 2020 , ... dicentra , a leading Contract Research ... is pleased to announce that Charles Galea has joined its clinical trials division ... an accomplished and results-driven sales executive with over 10 years of expertise in ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief ... clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an ...
Breaking Biology Technology:
Cached News: